Clinical Trial Update: Castrate Resistant Prostate Cancer Enhertu Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Enhertu (trastuzumab deruxtecan) for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Washington D.C. Veterans Affairs Medical Center | Conditions: Prostate Cancer Metastatic, Prostate Cancer | Phase 2 | Status: RECRUITING